Ivonescimab continues to show strong efficacy and safety in multiple Phase III trials, with a BLA PDUFA date set for November 2026. Operating expenses and net loss increased sequentially, but the company maintains a robust cash position and no debt.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.